Article: Response Biomedical and Shionogi Collaborate on RAMP BNP Test For Congestive Heart Failure.

Response Biomedical Corp. (TSX-V: RBM) today announced a collaboration with Shionogi & Co., Ltd to develop a rapid quantitative RAMP test for BNP (B-type natriuretic peptide), a proprietary cardiovascular marker test to assist in the diagnosis and management of congestive heart failure. Response Biomedical will develop the new RAMP BNP Test for Shionogi which has exclusive rights to BNP in Japan. Shionogi will fund development and will be responsible for regulatory affairs, marketing and distribution of the RAMP BNP Test in the Japanese market.

"Having successfully completed the feasibility of the RAMP BNP Test, we are very excited to form a relationship with ...






Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!